Anyone here looking for the next DNDN?
AEZS = THE NEW DNDN...CHECK OUT ITS HUGE ONCOLOGICAL PIPELINE!!!
AEterna Zentaris Inc.
(NASDAQ:AEZS)
The company is pending a large inflow of news items for its extensive clinical pipeline, and sources tell us the news is edging towards the positive end. Here is an updated timeline of what to expect:
This may near $3 soon and reach as high as $20-$50 by next year or two. A current market cap of only $80M leaves the door open for plenty of shareholder value opportunities. They will also be attending the ASCO conference in June, increasing transparency and most likely the buying pressure as high profile sources and Wall Street continue to discover this undervalued company.
1) Bone Marrow Cancer: Developing perifosine, the first-in-class oral AKT inhibitor. A Phase III study, the last stage before commercialization, is currently being conducted in the United States for myeloma, a form of bone marrow cancer. Perifosine has been granted a fast-track designation and orphan-drug designation by the FDA.
2) Colon cancer: Keryx is about to start a Phase III study with this same compound in metastatic colon cancer
3) Endometrial cancer and Ovarian cancer: AEZS-108. Conducting a Phase II study in Europe for endometrial cancer and ovarian cancer. We expect to disclose the final results later this year.
4) Bladder cancer, pancreatic cancer and prostate cancer: We also look to possibly conduct other clinical studies in bladder cancer, and pancreatic cancer and refractory prostate cancer
5) In vitro fertilization: In endocrinology we already have a marketed product for in vitro fertilization under the brand name Cetrotide(c). It is being marketed worldwide by Merck Serono, except in Japan, where it's marketed by Nippon Kayaku and Shionogi.
6) Growth hormone deficiency: Our lead endocrinology compound in late-stage development is AEZS-130, which is in Phase III as a diagnostic test for growth hormone deficiency . We also have an orphan-drug designation for this drug in the United States.
7) Currently in discussions with the FDA in order to find the best way to finalize this study for AEZS-130 and file for an approval at the end of this year
8) Children diagnostic test: We are also aiming for diagnostic use of AEZS-130 in children. And the unique selling point of this project is that this will be the first oral diagnostic test.
9) Treat cachexia: AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia, a condition which results in a severe reduction of muscle mass and weight loss in patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS and certain cancers.
10) At the pre-clinical development stage, we have some very unique molecules which are dual inhibitors of PI3K and Erk, two hot targets in oncology at present, and also a selective Erk inhibitor.
11) Some of these early-stage projects as well as our more advanced ones will be the object of presentations at major conferences throughout 2010, such as the American Society of Clinical Oncology, ASCO, and American Association of Cancer Research meetings.
